

and adopt, as well, and we can move forward in such a positive direction for people that you heard about today from my colleagues.

Lives that are on the line can be saved by innovation. The quicker we get that innovation to the market, the more we can reduce costs and save lives.

Mr. Speaker, I call on my colleagues to support passage of this very important lifesaving legislation, and I yield back the balance of my time.

Ms. ESHOO. Mr. Speaker, I rise today in support of H.R. 2430, the FDA Reauthorization Act of 2017 to reauthorize four important user fee programs: the Prescription Drug User Fee Act, the Medical Device User Fee Act, the Generic Drug User Fee Act, and the Biosimilar User Fee Act. These critically important laws have improved patient access to important therapies and expedited the FDA's approval times while upholding the most rigorous standards for patient safety.

The Prescription Drug User Fee Act (PDUFA) was enacted in 1992 when drug review times were lagging and FDA simply couldn't keep up with the flood of new drug applications. Through user fees paid by applicants, PDUFA gave FDA the resources it needed to hire and support more staff. The program has been successful in reducing review-time backlogs and expediting safe and effective therapies to patients.

My legislation created the Medical Device User Fee Act (MDUFA), which was enacted in 2002 and has resulted in significant changes to the medical device industry and within the medical device center at the FDA. Through this user fee program, the device center has improved its efficiency and reduced the time it takes to bring effective medical devices to market. This legislation builds on the progress made in previous user fee agreements and will produce important developments for the medical device industry.

The Generic Drug User Fee Agreement (GDUFA) was enacted in 2012 and takes important steps to bring lower-priced drugs to the market more quickly for the American people. Finally, the Biosimilar User Fee Agreement (BsUFA), which was first enacted in 2012 through legislation I authored, is critical to supporting the nascent biosimilar industry and will lead to meaningful progress, breakthroughs and cures for the American people.

Previous user fee reauthorizations have included significant gains for pediatric populations. Before the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), which I authored, the vast majority of drugs (more than 80 percent) used in children were used off-label, without data for their safety and efficacy. Today, that number has been reduced to 50 percent because of my legislation. Both programs were permanently reauthorized in 2012, and while this agreement includes important changes to BPCA and PREA, there remains a need for more meaningful improvements. This legislation lays important groundwork and provides the foundation for future progress.

Finally, I urge my colleagues in the Senate to take up this legislation swiftly. It's imperative that both houses of Congress pass this legislation and send it to the President in a timely manner for him to sign into law in order to provide essential resources to the FDA so they can continue to do their critical work.

Ms. MATSUI. Mr. Speaker, I rise today in support of H.R. 2430, the FDA user fee reauthorization bill that I worked on with my colleagues on the Energy & Commerce Committee.

Without Congress' swift action to reauthorize this bill, the FDA would not be able to conduct its critical work ensuring that our nation's drugs and devices are safe and effective.

Patients and families across the country battling diseases like Alzheimer's, cancer, multiple sclerosis (MS), and diabetes, rely on innovation to provide new life-saving and life-enhancing treatments and hopefully one day, cures. Without the FDA, we would not be able to ensure that those treatments and cures work and that they're safe.

To quote Dr. Jeff Allen of the Friends of Cancer Research, "for the people who currently depend on safe and effective medicines . . . for those who are holding strong for breakthroughs to come . . . and for every future patient . . . there isn't time to waste."

I urge my colleagues to support the passage of this bill.

Mrs. MIMI WALTERS of California. Mr. Speaker, I am pleased that the House is considering H.R. 2430, the FDA Reauthorization Act of 2017. I note that H.R. 2430 would provide the U.S. Food and Drug Administration (FDA) with new statutory authority to require the sponsor of an orphan-designated drug, which has certain similarities to an already approved drug, to demonstrate "clinical superiority" compared to the already approved drug as a condition of receiving seven years of market exclusivity.

This authority will limit the number of drugs that are automatically entitled to seven years of exclusivity, while maintaining incentives for the development of innovative treatments for rare diseases.

I also note that the bill would improve transparency of the FDA's execution of the Orphan Drug Act. Specifically, the bill directs the FDA to notify a sponsor in writing of any clinical superiority rationale on which the FDA relied in designating the sponsor's drug as an orphan drug. Further, it would require the FDA to publish its clinical superiority findings summaries for all drugs granted exclusivity based on a demonstration of clinical superiority.

I urge my colleagues to support the FDA Reauthorization Act of 2017.

The SPEAKER pro tempore (Mr. MURPHY of Pennsylvania). The question is on the motion offered by the gentleman from Oregon (Mr. WALDEN) that the House suspend the rules and pass the bill, H.R. 2430, as amended.

The question was taken; and (two-thirds being in the affirmative) the rules were suspended and the bill, as amended, was passed.

A motion to reconsider was laid on the table.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, proceedings will resume on questions previously postponed.

Votes will be taken in the following order:

Ordering the previous question on House Resolution 431;

Adopting House Resolution 431, if ordered; and

Suspending the rules and passing H.R. 1492.

The first electronic vote will be conducted as a 15-minute vote. Remaining electronic votes will be conducted as 5-minute votes.

PROVIDING FOR CONSIDERATION OF H.R. 2810, NATIONAL DEFENSE AUTHORIZATION ACT FOR FISCAL YEAR 2018, AND PROVIDING FOR CONSIDERATION OF H.R. 23, GAINING RESPONSIBILITY ON WATER ACT OF 2017

The SPEAKER pro tempore. The unfinished business is the vote on ordering the previous question on the resolution (H. Res. 431) providing for consideration of the bill (H.R. 2810) to authorize appropriations for fiscal year 2018 for military activities of the Department of Defense and for military construction, to prescribe military personnel strengths for such fiscal year, and for other purposes, and providing for consideration of the bill (H.R. 23) to provide drought relief in the State of California, and for other purposes, on which the yeas and nays were ordered.

The Clerk read the title of the resolution.

The SPEAKER pro tempore. The question is on ordering the previous question.

The vote was taken by electronic device, and there were—yeas 234, nays 183, not voting 16, as follows:

[Roll No. 347]

YEAS—234

Abraham	Cramer	Harper
Aderholt	Crawford	Harris
Allen	Culberson	Hartzler
Amash	Curbelo (FL)	Hensarling
Amodei	Davidson	Herrera Beutler
Arrington	Davis, Rodney	Hice, Jody B.
Babin	Denham	Higgins (LA)
Bacon	Dent	Hill
Banks (IN)	DeSantis	Holding
Barletta	DesJarlais	Hollingsworth
Barton	Diaz-Balart	Hudson
Bergman	Donovan	Huizenga
Biggs	Duffy	Hultgren
Billirakis	Duncan (SC)	Hunter
Bishop (MI)	Duncan (TN)	Hurd
Bishop (UT)	Dunn	Issa
Black	Emmer	Jenkins (KS)
Blackburn	Estes (KS)	Jenkins (WV)
Blum	Farenthold	Johnson (LA)
Bost	Faso	Johnson (OH)
Brady (TX)	Ferguson	Jones
Brat	Fitzpatrick	Jordan
Bridenstine	Fleischmann	Joyce (OH)
Brooks (AL)	Flores	Katko
Brooks (IN)	Fortenberry	Kelly (MS)
Buchanan	Fox	Kelly (PA)
Buck	Franks (AZ)	King (IA)
Budd	Frelinghuysen	King (NY)
Burgess	Gaetz	Kinziger
Byrne	Gallagher	Knight
Calvert	Garrett	Kustoff (TN)
Carter (GA)	Gianforte	Labrador
Carter (TX)	Gibbs	LaHood
Chabot	Gohmert	LaMalfa
Cheney	Goodlatte	Lamborn
Coffman	Gosar	Lance
Cole	Gowdy	Latta
Collins (GA)	Granger	Lewis (MN)
Collins (NY)	Graves (GA)	LoBiondo
Comer	Graves (LA)	Long
Comstock	Graves (MO)	Loudermilk
Conaway	Griffith	Love
Cook	Grothman	Lucas
Costello (PA)	Handel	Luetkemeyer

MacArthur
Marchant
Marino
Marshall
Massie
Mast
McCarthy
McCaul
McClintock
McHenry
McKinley
McMorris
Rodgers
McSally
Meadows
Meehan
Messer
Mitchell
Moolenaar
Mooney (WV)
Mullin
Murphy (PA)
Newhouse
Noem
Norman
Nunes
Olson
Palazzo
Palmer
Paulsen
Pearce
Perry
Pittenger
Poe (TX)
Poliquin

Posey
Ratcliffe
Reed
Reichert
Renacci
Rice (SC)
Roby
Roe (TN)
Rogers (AL)
Rogers (KY)
Rohrabacher
Rokita
Rooney, Francis
Rooney, Thomas J.
Ros-Lehtinen
Roskam
Ross
Rothfus
Rouzer
Royce (CA)
Russell
Rutherford
Sanford
Schweikert
Scott, Austin
Sessions
Shimkus
Shuster
Simpson
Smith (MO)
Smith (NE)
Smith (NJ)
Smith (TX)

Smucker
Stefanik
Stewart
Stivers
Taylor
Tenney
Thompson (PA)
Thornberry
Tiberi
Tipton
Trott
Turner
Upton
Valadao
Wagner
Walberg
Walden
Walker
Walorski
Walters, Mimi
Weber (TX)
Webster (FL)
Wenstrup
Westerman
Williams
Wilson (SC)
Wittman
Womack
Woodall
Yoder
Yoho
Young (AK)
Young (IA)
Zeldin

NAYS—183

Adams
Aguilar
Barragán
Bass
Beatty
Bera
Beyer
Bishop (GA)
Blumenauer
Blunt Rochester
Bonamici
Boyle, Brendan F.
Brady (PA)
Brown (MD)
Brownley (CA)
Bustos
Butterfield
Capuano
Carbajal
Cárdenas
Carson (IN)
Cartwright
Castor (FL)
Castro (TX)
Chu, Judy
Cicilline
Clark (MA)
Clarke (NY)
Clay
Cleaver
Clyburn
Cohen
Connolly
Conyers
Cooper
Correa
Courtney
Crist
Cuellar
Davis (CA)
Davis, Danny
DeFazio
DeGette
Delaney
DeLauro
DelBene
Demings
DeSaulnier
Deutch
Dingell
Doggett
Doyle, Michael F.
Ellison
Engel
Eshoo
Espallat
Esty (CT)
Evans
Foster

Frankel (FL)
Fudge
Gabbard
Gallego
Garamendi
Gomez
Gonzalez (TX)
Gottheimer
Green, Al
Green, Gene
Grijalva
Gutiérrez
Hanabusa
Hastings
Heck
Higgins (NY)
Himes
Hoyer
Huffman
Jackson Lee
Jayapal
Jeffries
Johnson (GA)
Johnson, E. B.
Kaptur
Keating
Kelly (IL)
Kennedy
Kihuen
Kildee
Kilmer
Kind
Krishnamoorthi
Kuster (NH)
Langevin
Larsen (WA)
Larson (CT)
Lawrence
Lawson (FL)
Lee
Levin
Lewis (GA)
Lipinski
Loebach
Loebach
Lowey
Lujan Grisham, M.
Luján, Ben Ray
Lynch
Maloney
Carolyn B.
Maloney, Sean
Matsui
McCollum
McEachin
McGovern
McNerney
Meeks
Meng

Moore
Moulton
Murphy (FL)
Nadler
Neal
Nolan
Norcross
O'Halleran
O'Rourke
Pallone
Panetta
Pascarelli
Payne
Perlmutter
Peters
Peterson
Pingree
Pocan
Polis
Price (NC)
Quigley
Raskin
Rice (NY)
Richmond
Rosen
Roybal-Allard
Ruiz
Ruppersberger
Rush
Ryan (OH)
Sánchez
Sarbanes
Schakowsky
Schneider
Schradler
Scott (VA)
Scott, David
Serrano
Sewell (AL)
Sherman
Sinema
Slaughter
Smith (WA)
Soto
Speier
Suozi
Swalwell (CA)
Takano
Thompson (CA)
Thompson (MS)
Titus
Tonko
Tsongas
Vargas
Veasey
Vela
Velázquez
Visclosky
Walz
Wasserman

SchultzWaters, Maxine
Watson Coleman Welch
Wilson (FL) Yarmuth

Johnson, Sam
Khanna
Lieu, Ted
Napolitano
Pelosi
Scalise

NOT VOTING—16

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE
The SPEAKER pro tempore (during the vote). There are 2 minutes remaining.

□ 1444

Messrs. LOEBSACK and DAVID SCOTT of Georgia changed their vote from “yea” to “nay.”

So the previous question was ordered.
The result of the vote was announced as above recorded.

Stated against:

Mr. SCHIFF. Mr. Speaker, I was unavoidably detained. Had I been present, I would have voted “nay” on rollcall No. 347.

The SPEAKER pro tempore. The question is on the resolution.

The question was taken; and the Speaker pro tempore announced that the ayes appeared to have it.

RECORDED VOTE

Mr. HASTINGS. Mr. Speaker, I demand a recorded vote.

A recorded vote was ordered.

The SPEAKER pro tempore. This will be a 5-minute vote.

The vote was taken by electronic device, and there were—ayes 232, noes 187, not voting 14, as follows:

[Roll No. 348]

AYES—232

Abraham
Aderholt
Allen
Amash
Amodei
Arrington
Babin
Bacon
Banks (IN)
Barton
Bergman
Biggs
Bilirakis
Bishop (MI)
Bishop (UT)
Black
Blackburn
Blum
Bost
Brady (TX)
Brat
Bridenstine
Brooks (AL)
Brooks (IN)
Buchanan
Buck
Bucshon
Budd
Burgess
Byrne
Calvert
Carter (GA)
Carter (TX)
Chabot
Cheney
Coffman
Cole
Collins (GA)
Collins (NY)
Comer
Comstock
Conaway
Cook
Costello (PA)
Cramer
Crawford

Culberson
Curbelo (FL)
Davidson
Davis, Rodney
Denham
Dent
DeSantis
DesJarlais
Diaz-Balart
Donovan
Duffy
Duncan (SC)
Duncan (TN)
Dunn
Emmer
Estes (KS)
Farenthold
Faso
Ferguson
Fitzpatrick
Fleischmann
Flores
Fortenberry
Foxy
Franks (AZ)
Frelinghuysen
Gaetz
Gallagher
Garrett
Lance
Gibbs
Goodlatte
Gosar
Gowdy
Granger
Graves (GA)
Graves (LA)
Graves (MO)
Griffith
Grothman
Handel
Harper
Harris
Hartzler
Herrera Beutler
Hice, Jody B.

Higgins (LA)
Hill
Holding
Hollingsworth
Hudson
Huizenga
Hultgren
Hunter
Hurd
Issa
Jenkins (KS)
Jenkins (WV)
Johnson (LA)
Johnson (OH)
Jones
Jordan
Joyce (OH)
Katko
Kelly (MS)
Kelly (PA)
King (IA)
King (NY)
Kinzinger
Knight
Kustoff (TN)
Labrador
LaHood
LaMalfa
Lamborn
Lance
Latta
Lewis (MN)
LoBiondo
Long
Loudermilk
Love
Lucas
Luetkemeyer
MacArthur
Marchant
Marino
Marshall
Massie
Mast
McCarthy
McCaul

McClintock
McHenry
McKinley
McMorris
Rodgers
McSally
Meadows
Meehan
Messer
Mitchell
Moolenaar
Mooney (WV)
Mullin
Murphy (PA)
Newhouse
Noem
Norman
Nunes
Olson
Palazzo
Palmer
Paulsen
Pearce
Perry
Pittenger
Poe (TX)
Poliquin
Posey
Ratcliffe
Reed
Reichert
Renacci

Rice (SC)
Roby
Roe (TN)
Rogers (AL)
Rogers (KY)
Rohrabacher
Rokita
Rooney, Francis
Rooney, Thomas J.
Ros-Lehtinen
Roskam
Ross
Rothfus
Rouzer
Royce (CA)
Russell
Rutherford
Sanford
Schweikert
Scott, Austin
Sensenbrenner
Sessions
Shimkus
Shuster
Simpson
Smith (MO)
Smith (NE)
Smith (NJ)
Smith (TX)
Smucker
Stefanik

Stewart
Stivers
Taylor
Tenney
Thompson (PA)
Thornberry
Tiberi
Tipton
Trott
Turner
Upton
Valadao
Wagner
Walberg
Walden
Walker
Walorski
Walters, Mimi
Weber (TX)
Webster (FL)
Wenstrup
Westerman
Williams
Wilson (SC)
Wittman
Womack
Woodall
Yoder
Yoho
Young (AK)
Young (IA)
Zeldin

NOES—187

Adams
Aguilar
Barragán
Bass
Beatty
Bera
Beyer
Bishop (GA)
Blumenauer
Blunt Rochester
Bonamici
Boyle, Brendan F.
Brady (PA)
Brown (MD)
Brownley (CA)
Bustos
Butterfield
Capuano
Carbajal
Cárdenas
Carson (IN)
Cartwright
Castor (FL)
Castro (TX)
Chu, Judy
Cicilline
Clark (MA)
Clarke (NY)
Clay
Cleaver
Clyburn
Cohen
Connolly
Conyers
Cooper
Correa
Courtney
Crist
Cuellar
Davis (CA)
Davis, Danny
DeFazio
DeGette
Delaney
DeLauro
DelBene
Demings
DeSaulnier
Deutch
Dingell
Doggett
Doyle, Michael F.
Ellison
Engel
Eshoo
Espallat
Esty (CT)
Evans
Foster

Gallego
Garamendi
Gohmert
Gomez
Gonzalez (TX)
Gottheimer
Green, Al
Green, Gene
Grijalva
Gutiérrez
Hanabusa
Hastings
Heck
Higgins (NY)
Himes
Hoyer
Huffman
Jackson Lee
Jayapal
Jeffries
Johnson (GA)
Johnson, E. B.
Kaptur
Keating
Kelly (IL)
Kennedy
Kihuen
Kildee
Kilmer
Kind
Krishnamoorthi
Kuster (NH)
Langevin
Larsen (WA)
Larson (CT)
Lawrence
Lawson (FL)
Lee
Levin
Lewis (GA)
Lipinski
Loebach
Loebach
Lowey
Lujan Grisham, M.
Luján, Ben Ray
Lynch
Maloney
Carolyn B.
Maloney, Sean
Matsui
McCollum
McEachin
McGovern
McNerney
Meeks
Meng

Nolan
Norcross
O'Halleran
O'Rourke
Pallone
Panetta
Pascarelli
Payne
Perlmutter
Peters
Peterson
Pingree
Pocan
Polis
Price (NC)
Quigley
Raskin
Rice (NY)
Richmond
Rosen
Roybal-Allard
Ruiz
Ruppersberger
Rush
Ryan (OH)
Sánchez
Sarbanes
Schakowsky
Schiff
Schneider
Schradler
Scott (VA)
Scott, David
Serrano
Sewell (AL)
Sherman
Sinema
Sires
Slaughter
Smith (WA)
Soto
Speier
Suozi
Swalwell (CA)
Takano
Thompson (CA)
Thompson (MS)
Titus
Tonko
Torres
Tsongas
Vargas
Veasey
Vela
Velázquez
Visclosky
Walz
Wasserman
Schultz
Waters, Maxine
Watson Coleman
Welch
Wilson (FL)
Yarmuth

NOT VOTING—14

Barletta	Guthrie	Napolitano
Barr	Hensarling	Pelosi
Costa	Johnson, Sam	Scalise
Crowley	Khanna	Shea-Porter
Cummings	Lieu, Ted	

□ 1452

Mr. LOEBSACK changed his vote from “aye” to “no.”

So the resolution was agreed to.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

ANNOUNCEMENT BY COMMITTEE ON RULES REGARDING AMENDMENT PROCESS FOR H.R. 806, OZONE STANDARDS IMPLEMENTATION ACT OF 2017, AND H.R. 2997, 21ST CENTURY AVIATION INNOVATION, REFORM, AND REAUTHORIZATION ACT

Mr. SESSIONS. Mr. Speaker, this morning the Rules Committee issued announcements outlining the amendment processes for two measures that will likely be before the Rules Committee next week.

An amendment deadline has been set for Monday, July 17, at 10 a.m., for H.R. 806, the Ozone Standards Implementation Act of 2017; and Monday, July 17, at noon, for H.R. 2997, the 21st Century AIRR Act.

The text of these measures is presently available on the Rules Committee website.

Feel free to contact me or my staff if we may provide any additional information.

MEDICAL CONTROLLED SUBSTANCES TRANSPORTATION ACT OF 2017

The SPEAKER pro tempore. Without objection, 5-minute will continue.

There was no objection.

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and pass the bill (H.R. 1492) to amend the Controlled Substances Act to direct the Attorney General to register practitioners to transport controlled substances to States in which the practitioner is not registered under the Act for the purpose of administering the substances (under applicable State law) at locations other than principal places of business or professional practice, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Texas (Mr. BURGESS) that the House suspend the rules and pass the bill.

This is a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 416, nays 2, not voting 15, as follows:

[Roll No. 349]

YEAS—416

Abraham	DeBene	Jordan
Adams	Demings	Joyce (OH)
Aderholt	Denham	Kaptur
Aguilar	Dent	Katko
Allen	DeSantis	Keating
Amash	DeSaulnier	Kelly (IL)
Amodei	DesJarlais	Kelly (MS)
Arrington	Deutch	Kelly (PA)
Babin	Diaz-Balart	Kennedy
Bacon	Dingell	Kihuen
Banks (IN)	Doggett	Kildee
Barletta	Donovan	Kilmer
Barragan	Doyle, Michael	Kind
Barton	F.	King (IA)
Bass	Duffy	King (NY)
Beatty	Duncan (SC)	Kinzinger
Bera	Duncan (TN)	Knight
Bergman	Dunn	Krishnamoorthi
Beyer	Ellison	Kuster (NH)
Biggs	Emmer	Kustoff (TN)
Bilirakis	Engel	Labrador
Bishop (GA)	Eshoo	LaMalfa
Bishop (MI)	Espallat	Lamborn
Bishop (UT)	Estes (KS)	Lance
Black	Esty (CT)	Langevin
Blackburn	Evans	Larsen (WA)
Blum	Farenthold	Larson (CT)
Blumenauer	Faso	Latta
Blunt Rochester	Ferguson	Lawrence
Bonamici	Fitzpatrick	Lawson (FL)
Bost	Fleischmann	Lee
Boyle, Brendan	Flores	Levin
F.	Fortenberry	Lewis (GA)
Brady (PA)	Foster	Lewis (MN)
Brady (TX)	Fox	Lipinski
Brat	Frankel (FL)	LoBiondo
Bridenstine	Franks (AZ)	Loebsack
Brooks (AL)	Frelinghuysen	Lofgren
Brooks (IN)	Fudge	Long
Brown (MD)	Gabbard	Loudermilk
Brownley (CA)	Gaetz	Love
Buchanan	Gallagher	Lowenthal
Buck	Galleo	Lowey
Bucshon	Garamendi	Lucas
Budd	Garrett	Luetkemeyer
Burgess	Gianforte	Lujan Grisham,
Bustos	Gibbs	M.
Butterfield	Gomez	Lujan, Ben Ray
Byrne	Gonzalez (TX)	Lynch
Calvert	Goodlatte	MacArthur
Capuano	Gosar	Maloney,
Carbajal	Gottheimer	Carolyn B.
Cárdenas	Gowdy	Maloney, Sean
Carson (IN)	Granger	Marchant
Carter (GA)	Graves (GA)	Marino
Carter (TX)	Graves (LA)	Marshall
Cartwright	Graves (MO)	Mast
Castor (FL)	Green, Al	Matsui
Castro (TX)	Green, Gene	McCarthy
Chabot	Griffith	McCaul
Cheney	Grijalva	McClintock
Chu, Judy	Grothman	McCollum
Cicilline	Hanabusa	McEachin
Clark (MA)	Handel	McGovern
Clarke (NY)	Harper	McHenry
Clay	Harris	McKinley
Cleaver	Hartzler	McMorris
Clyburn	Hastings	Rodgers
Coffman	Heck	McNerney
Cohen	Hensarling	McSally
Cole	Herrera Beutler	Meadows
Collins (GA)	Hice, Jody B.	Meehan
Collins (NY)	Higgins (LA)	Meeks
Comer	Higgins (NY)	Meng
Comstock	Hill	Messer
Conaway	Himes	Mitchell
Connolly	Holding	Moolenaar
Conyers	Hollingsworth	Mooney (WV)
Cook	Hoyer	Moore
Cooper	Hudson	Moulton
Correa	Huffman	Mullin
Costello (PA)	Huizenga	Murphy (FL)
Courtney	Hultgren	Murphy (PA)
Cramer	Hunter	Nadler
Crawford	Hurd	Neal
Crist	Issa	Newhouse
Cuellar	Jackson Lee	Noem
Culberson	Jayapal	Nolan
Curbelo (FL)	Jeffries	Norcross
Davis (CA)	Jenkins (KS)	Norman
Davis, Danny	Jenkins (WV)	Nunes
Davis, Rodney	Johnson (GA)	O'Halleran
DeFazio	Johnson (LA)	O'Rourke
DeGette	Johnson (OH)	Olson
Delaney	Johnson, E. B.	Palazzo
DeLauro	Jones	Pallone

Palmer	Ruppersberger	Thompson (PA)
Panetta	Rush	Thornberry
Pascrell	Russell	Tiberi
Paulsen	Rutherford	Tipton
Payne	Ryan (OH)	Titus
Pearce	Sánchez	Tonko
Pelosi	Sanford	Torres
Perlmutter	Sarbanes	Trott
Perry	Schakowsky	Tsongas
Peters	Schiff	Turner
Peterson	Schneider	Upton
Pingree	Schrader	Valadao
Pittenger	Schweikert	Vargas
Pocan	Scott (VA)	Veasey
Poe (TX)	Scott, Austin	Vela
Poliquin	Scott, David	Velázquez
Polis	Sensenbrenner	Visclosky
Posey	Serrano	Wagner
Price (NC)	Sessions	Walberg
Quigley	Sewell (AL)	Walden
Raskin	Sherman	Walker
Ratcliffe	Shimkus	Walorski
Reichert	Shuster	Walters, Mimi
Renacci	Simpson	Walz
Rice (NY)	Sinema	Wasserman
Rice (SC)	Sires	Schultz
Richmond	Slaughter	Waters, Maxine
Roby	Smith (MO)	Watson Coleman
Roe (TN)	Smith (NE)	Weber (TX)
Rogers (AL)	Smith (NJ)	Webster (FL)
Rogers (KY)	Smith (TX)	Welch
Rohrabacher	Smith (WA)	Wenstrup
Rokita	Smucker	Westerman
Rooney, Francis	Soto	Williams
Rooney, Thomas	Speier	Wilson (FL)
J.	Stefanik	Wilson (SC)
Ros-Lehtinen	Stewart	Wittman
Rosen	Stivers	Womack
Roskam	Suozzi	Woodall
Ross	Swalwell (CA)	Yarmuth
Rothfus	Takano	Yoder
Rouzer	Taylor	Yoho
Roybal-Allard	Tenney	Young (AK)
Royce (CA)	Thompson (CA)	Young (IA)
Ruiz	Thompson (MS)	Zeldin

NAYS—2

Gohmert

Massie

NOT VOTING—15

Barr	Guthrie	Lieu, Ted
Costa	Gutiérrez	Napolitano
Crowley	Johnson, Sam	Reed
Cummings	Khanna	Scalise
Davidson	LaHood	Shea-Porter

□ 1506

So (two-thirds being in the affirmative), the rules were suspended and the bill was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

PERSONAL EXPLANATION

Mrs. NAPOLITANO. Mr. Speaker, I was absent during rollcall votes No. 347, No. 348, and No. 349 due to my spouse's health situation in California. Had I been present, I would have voted “nay” on the Motion on Ordering the Previous Question on the Rule providing for consideration of both H.R. 23 and H.R. 2810. I would have also voted “nay” on H. Res. 431—Rule providing for consideration of both H.R. 23—Gaining Responsibility on Water Act of 2017 and H.R. 2810—National Defense Authorization Act for Fiscal Year 2018. I would have also voted “yea” on H.R. 1492—Medical Controlled Substances Transportation Act of 2017.

PERSONAL EXPLANATION

Mr. CROWLEY. Mr. Speaker, on July 12, 2017, due to a family commitment I was absent for recorded votes No. 347, No. 348, and No. 349. Had I been present, on rollcall No. 347, I would have voted “no”; on rollcall No. 348, I would have voted “no”; and on rollcall No. 349, I would have voted “yes.”